Study S000507

A Multicenter, Randomized, Open-label Phase III Study to Compare the Efficacy and Safety of IBI362 and Semaglutide in Chinese Overweight or Obese Subjects With Metabolic Dysfunction-associated Fatty Liver Disease (GLORY-3)

ClinicalTrials.gov record

Registration

Registration: NCT06884293
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 479
Start: 2025-05-09
Primary completion: 2026-12-31
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Conditions: Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
Interventions: DRUG:IBI362; DRUG:semaglutide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

percentage change in body weight from baseline [at Week 48]
percentage change in liver fat content from baseline measured by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF) [at Week 48]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.